Cellectis Presents Lasme-cel Phase 1 Data Showing Manageable Safety Profile With CRS Grade 3 In 4% Of Patients And Eti-cel Achieving 63% Complete Response In r/r B-NHL

Benzinga Newsdesk www.benzinga.com Positive 95.4%

Neg 0% Neu 0% Pos 95.4%

Comments

No comments yet. Be the first!